

CITATION REPORT

List of articles citing

Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus

DOI: 10.1001/jamadermatol.2019.3236

JAMA Dermatology, 2019, 155, 1404-1409.

Source: <https://exaly.com/paper-pdf/72283089/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
36	. <i>Annales De Dermatologie Et De Venereologie</i> , 2020 , 147, 12S43-12S50	0.3	
35	Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience. <i>Dermatology</i> , 2021 , 237, 179-184	4.4	2
34	Novel Therapies for Pemphigus Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 765-782	7.1	2
33	Long-term outcomes of rituximab therapy in pemphigus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2884-2889	4.6	11
32	Rationale for including intravenous immunoglobulin in the multidrug protocol of curative treatment of pemphigus vulgaris and development of an assay predicting disease relapse. <i>International Immunopharmacology</i> , 2020 , 82, 106385	5.8	1
31	Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 523-524	1.6	1
30	Prednisone/rituximab. <i>Reactions Weekly</i> , 2020 , 1789, 230-230	0	
29	Reader Comment on "Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris". <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 25, 111-112	1.6	
28	Reply to Reader Comment on "Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris". <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 25, 113-114	1.6	
27	Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. <i>Dermatologic Therapy</i> , 2021 , 34, e14633	2.2	4
26	Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris. <i>British Journal of Dermatology</i> , 2021 , 184, 573-575	4	1
25	Treatment of Pemphigus with Rituximab: Real-Life Experience in a Cohort of 117 Patients in Israel. <i>Dermatology</i> , 2021 , 237, 450-456	4.4	2
24	Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease. <i>Journal of Immunology</i> , 2021 , 206, 669-675	5.3	2
23	The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 443-454	5.4	1
22	Rituximab Therapy for Treatment of Pemphigus in Southeast Asians. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 1677-1690	4.4	3
21	B-cell targeted therapies in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021 , 156,	1.2	0
20	Pemphigus: a critical analysis on clinical subtypes, pathogenesis, diagnostics and established novel therapeutics. <i>Italian Journal of Dermatology and Venereology</i> , 2021 , 156,	1.2	0

19	Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus. <i>Journal of Dermatological Treatment</i> , 2021 , 1-8	2.8	0
18	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1523-1537	4.5	5
17	Biologics in autoimmune bullous diseases: Current scenario. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021 , 87, 611-620	0.8	0
16	On the road to eliminating long-lived plasma cells-"are we there yet?". <i>Immunological Reviews</i> , 2021 , 303, 154-167	11.3	3
15	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6317-6324	15.9	25
14	Temporal outcomes after rituximab therapy for pemphigus vulgaris. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	2
13	An Updated Review of Pemphigus Diseases. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	2
12	Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic. <i>Biomedicines</i> , 2021 , 9,	4.8	1
11	Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	1
10	Autoimmune Pemphigus: Latest Advances and Emerging Therapies.. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 808536	5.6	1
9	Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?. <i>Dermatologic Therapy</i> , 2021 , e15249	2.2	6
8	Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients.. <i>Dermatologic Therapy</i> , 2022 , e15397	2.2	1
7	Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.. <i>Frontiers in Immunology</i> , 2022 , 13, 884931	8.4	0
6	Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.. <i>American Journal of Clinical Dermatology</i> , 2022 ,	7.1	0
5	Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus. <i>JAMA Dermatology</i> ,	5.1	
4	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 9,	4.9	3
3	Pemphigus for the Inpatient Dermatologist.		0
2	Off-Label Uses of Rituximab in Dermatology.		1

- 1 Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.

o